What Should I Build?

A directory of what people actually want. Classified, clustered, ranked and updated daily

Regulatory acceleration SaaS for gene-editing & rare disease approvals

Other · 1 mentions

#2007147312943190309

@techinvestoor Agreed. The FDA is too slow for the gene-editing era. To beat China, we need a total overhaul of rare disease approvals. Policy reform + funding are vital to stay ahead in medical innovation. 🧬 $PRME @US_FDA

For any inquiries, contact info@quantumedge.sk